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The antimicrobial activity of polymorphonuclear leukocytes (PMN)' depends
both on reduction products of02 that are generated de novo upon contact with the
pathogen (1), and preformed polypeptides that are stored in lysosomes for delivery
to nascent phagosomes (2, 3). Well-characterized microbicidal polypeptides from
neutrophils include (in decreasing order ofMr): bactericidal/permeability-increasing
protein (BPI, 58 x 103) (4), probably closely related to cationic antimicrobial pep-
tide (CAP, 57 x 103 [5]); cathepsin G(25-29 x 103) (6); lysozyme (14 x 103) (7);
defensins (3.3 x 103) (8); and bactenecin (N1.6 x 103) (9). Each of these cationic
proteins has a characteristic spectrum ofmicrobicidal activity. Some selectively kill
Gram-negative (BPI, CAP) orGram-positive organisms (lysozyme); others killboth
Gram-negative and Gram-positive bacteria as well as fungi (defensins, cathepsinG).
Cytotoxic polypeptides from eosinophils include eosinophil-derived neurotoxin (18
x 103 Mr) (10), eosinophil cationic protein (17-20 x 103 Mr) (11), and major basic
protein (MBP, 13 x 103 Mr) (12). The eosinophil-derived proteins reportedly lack
microbicidal activity against Gram-negative or Gram-positive bacteria and fungi,
although they are toxic to helminths, protozoa, and mammalian cells (13).
Aspartofa systematic survey ofthe antimicrobialproteins ofhumanPMN (Gabay,
J., R. Scott, D. Campanelli, C. Wilde, J. Griffith, M. Seeger, C. Nathan, manu-
script in preparation), we purified a 14-kD protein associated with potent microbi-
cidal activity against Gram-negative and Gram-positive bacteria and fungi. The
N112-terminal sequence ofthis polypeptide proved to be identical to the NH2 ter-
minusofMBP(14). Additional amino acid sequencingallowedusto design oligonu-
cleotide probes which were used to screen a cDNA library made from a promyelo-
cytic leukemia cellline. From thislibrarywe isolated aclass ofcDNA clones encoding
a 25-kD polypeptide, which contained in its NH2-terminal halfa sequence predicted
to be hydrophilic and markedly acidic, and in its COOH-terminal halfthe MBP
sequence, which is, in contrast, hydrophobic and very basic.
This work was supported by grants AI-23807 and CA-43610 from the National Institutes of Health
and by grant BC-586 from the American Cancer Society. Address correspondence to J. Gabay, Box
57, Cornell University Medical College, 1300 York Avenue, New York, NY 10021 .
1 Abbreviations used in this paper . BPI, bactericidal/permeability-increasing protein; CAP, cationic anti-
microbial protein; KU, killing units; MBP, major basic protein; PMN, polymorphonuclear leukocyte(s).
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Materials and Methods
Isolation ofPMNProteins.
￿
Blood was obtained from healthy donors and processed as previ-
ously described (15). More than 98% ofthe cells were PMNs, of which 93-97°70 were neutro-
phils and 3-717o eosinophils. After nitrogen bomb cavitation, azurophil granules were sepa-
rated on discontinuous Percoll density gradients (15). Azurophil granule extracts were prepared
by freeze-thaw and sonication of the granules followed by centrifugation at 10,000 g for 60
min at 4°C . The pelleted material was extracted with 50 mM glycine-HCl buffer, pH 2.2
(15), centrifuged at 10,000 g for 20 min, and the supernatant was concentrated 20-fold using
a Centricon-10 microconcentrator of 10,000 Mr cutoff (Amicon Corp., Danvers, MA).
Purification ofMajor Basic Protein.
￿
Approximately 1 mg of the granule membrane extract
was applied to a Bio-Sil TSK-125 size exclusion column (Bio-Rad Laboratories, Richmond,
CA) equilibrated in 50 mM glycine/0.1 M NaCl, pH 2 .0, and eluted at a flow rate of 0.5
ml/min. Fractions were assayed for antimicrobial activity as described below. The low molec-
ular weight peak exhibiting both antifungal and antibacterial activity was adjusted to 0.1%
TFA and further purified by reverse-phase HPLC using a Vydac wide pore C4 (250 x 4
mm) column equilbrated in 0.1% TFA. Elution ofthe 14-kD polypeptide was performed with
a 0-48% acetonitrile gradient in 0.1% TFA at a flow rate of 1 ml/min on an HPLC System,
(Beckman Instruments, Inc., Fullerton, CA). The resolved peak was lyophilized after evapo-
ration of acetonitrile by flushing with oxygen-free nitrogen.
Amino Acid Sequence Analysis ofMBP
￿
Reverse-phase purified MBP was sequenced using
a pulsed liquid phase sequenator (model 477A; Applied Biosystems, Inc., Foster City, CA).
Phenylthiohydantoin analysis was performed on line using a PTH Analyzer, (model 120A;
Applied Biosystems, Inc.).
Assaysfor Antimicrobial Activity.
￿
Bactericidal activity was tested against Escherichia coli K12
(strain MC 4100) and Streptococcusfaecalis (ATCC 8043) as previously reported (15). Killing
assays were performed in 50 mM citrate buffer, pH 5.5 (E. colt), or 50 mM phosphate buffer,
pH 6.0 (S.faecalis). Fungicidal activity was tested against Candida albicans (clinical isolate from
Columbia Presbyterian Hospital, New York, NY). Sabouraud dextrose broth and Sabouraud
agar plates (Difco Laboratories, Detroit, MI) were used to cultivate fungi. Organisms from
a single colony on agar plates were inoculated into liquid medium and cultured for 24-48
h at 37°C. Aliquots of the subculture were inoculated into fresh nutrient broth and grown
to 7-8 x 106 organisms/ml, as determined with a counting chamber. C. albicans (1-2 x 104
CFU/ml) was incubated in 10 mM phosphate buffer, pH 5 .5, for 60 min at 37 °C with various
amounts of granule extract. Samples were then diluted 1 :10 in M63 minimal medium salts
(16) and spread onto agar plates. Antimicrobial activity was expressed as killing units (KU),
defined as the reciprocal of the dilution of granule extract necessary to kill 105 bacteria/ml
in 30 min at 37'C (LD5o) or 104 fungi/ml in 60 min at 37°C. Specific activity was expressed
as KU/mg protein.
Tissue Culture.
￿
The human promyelocytic leukemia cell line HL60 and the acute myelog-
enous leukemia cell line KGla were obtained from the American Type Culture Collection
(Rockville, MD). Both were maintained at 37'C in suspension culture at 0.5 to 2 .0 x 106
cells/ml in modified DME supplemented with 10% FCS, penicillin, streptomycin, and gluta-
mine. Cells were induced to differentiate with the addition of DMSO (Sigma Chemical Co.,
St. Louis, MO) by resuspending cells in fresh medium containing 1.0% DMSO at a concen-
tration of 106 cells/ml. Cultures were harvested at 40 h after induction, when cell viability
was >85%, and RNA was prepared immediately. The human adenocarcinoma cell line SK-
HEP-1 was obtained from American Type Culture Collection, and human foreskin fibroblast
cells (HFF) were obtained as a primary culture at passage 9 from Dr.Joffre Baker, University
of Kansas, Lawrence, KS. These cells were carried as monolayer cultures in complete DME
supplemented with 10% FCS.
Preparation ofmRNA andNorthern BlotAnalysis.
￿
Cytoplasmic RNA was isolated from clarified
extracts ofcells lysed with 0.4% NP-40 (Sigma Chemical Co.) in the presence of 10 mM vanadyl
complex by extraction with phenol-chloroform and precipitation with ethanol (17, 18). Poly-
adenylated mRNA was purified by oligo(dT) chromatography (19). Poly(A)-containing cyto-
plasmic RNA was denatured in formamide/formaldehyde buffer and 10-wg samples were ap-
plied to a 1 .5% agarose formaldehyde gel and electrophoresed at 60 V for 15 h (20). TheMcGROGAN ET AL.
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RNA was electrotransferred to a Genescreenmembrane according to the manufacturer's recom-
mendation (DuPont Co., Wilmington, DE).
Construction ofHuman cDNA Library.
￿
cDNA was synthesized from 5 ug of mRNA using
a modification of the method ofG6bler and Hoffman (21). The purified cDNA product was
cloned into the Eco RI site of XGT 10 according to the procedure of Huynh et al. (22). The
resulting cDNA libraries contained -2 x 106 independent recombinants with inserts >500
by for the uninduced library, or inserts >300 by for the DMSO-induced library. Approxi-
mately 106 recombinant phage were screened by hybridization of the 14-mer probe to dupli-
cate filter lifts (23).
Hybridization Procedures.
￿
DNA fragment probes were hybridized under standard condi-
tions in a buffer containing 50% formamide, 5 x SSC (1 x SSC = 0.15 M sodium chloride,
0 .015 M sodium citrate, pH 7.0), 2 x Denhardt's solution, 20 mM sodium phosphate buffer,
pH 7.0, 1 mM EDTA, 0.2% SDS, and 100 ug/ml yeast RNA at 42°C (18). Oligomer probe
hybridization was carried out at 32°C in oligomer hybridization buffer (6 x SSC, 0.2 % SDS,
2 x Denhardt's, 20 mM phosphate buffer, pH 7.0, 1 mM EDTA, and 100 wg/ml yeast RNA
[24]). The filters were washed at 25°C in 2 x SSC, 0.117o SDS, 10 mM phosphate, and then
were exposed to Kodak XAR x-ray film at -800C. The oligomer probes were labeled by
the addition of 32p to the 5' base using polynucleotide kinase and purified over a Bio-Gel
P-4 spin column (18). DNA fragment probes were labeled by nick translation (25) with DNA
Polymerase I in the presence of [32P]dCTP and were purified over a Bio-Gel P-60 spin
column.
Preparation ofHuman GenomicDNAandSouthern BlotAnalysis.
￿
High molecular weight genomic
DNA was prepared by SDS-proteinase K treatment and phenol-chloroform extractionofnuclei
isolated after lysis of -108 cells with 0.5% NP-40 (18). The purified genomic DNA was
digested to completionwith the appropriate restriction enzymes according to the manufac-
turer's recommendation. The restrictedDNA samples were extracted with phenol-chloroform,
precipitated with ethanol, and dissolved in gel sample buffer. The DNA was fractionated by
electrophoresis in an 0.8% agarose gel in Tris-borate buffer (18). The gel was processed and
electroblotted to a Genescreen membrane as described above.
DNAManipulations.
￿
DNA was purified from phage platelysates ofthe positively hybridizing
clones according to the method of Davis et al. (26) and subcloned into pUC plasmids for
large-scale preparations. Plasmid DNA was purified afteralkaline-SDS lysis(18) of saturated
cultures of JM101, followed by polyethylene glycol precipitation. Synthetic DNA was pre-
pared using a Gene Assembler (Pharmacia LKB Biotechnology, Inc., Piscataway, NJ) and
was purified on NENSORB prep columns (DuPont, NEN Research Products, Boston, MA).
DNASequencing andAnalysis.
￿
Restriction fragments encompassing the cDNA inserts were
inserted into phage M13 vectors mp18 and mp19 (27) and sequenced by the dideoxynucleo-
tide chain termination (28) method using E. coli DNA Polymerase I large fragment (DuPont
Co.) or T7 polymerase (U. S. Biochemicals) according to the manufacturers' recommenda-
tions. Sequence analysis was performed using the PC Gene programs (Intelligenetics Corp.,
Mountain View, CA) on a Compaq 386 microcomputer.
Results
Purification of MBP.
￿
Azurophil granule membranes (derived from 4 x 108
PMNs) were incubated at pH 2 .2 and the extracted proteins were concentrated and
separated using HPLC size-exclusion chromatography, as shown in Fig. 1. Frac-
tions were assayed for bactericidal and fungicidal activities. Both activitiescomigrated
in two peaks, one corresponding to polypeptides of 54 kD and 25-29 kD (fractions
30-35), and a smaller peak containing species of 18 kD and 14 kD (fractions 41-43) .
Further analysis of the high Mr peak revealed several antimicrobial proteins which
will be described separately (Gabay, J., et al., manuscript in preparation). Reverse-
phase HPLC of the low Mr fraction yielded one major and two minor peaks (Fig.
2). The major component, contained in fraction 30, was lyophilized, and 90% of2298
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FIGURE 1 .
￿
HPLC size-exclusion chro-
matography of azurophil membrane
extract . (A) Profile of the OD280 and
the bactericidal and fungicidal activity
of the eluted fractions . (B)SDS-PAGE
analysis offractions eluted from the gel
filtration column . Molecular weight
markers (1, 10), total granule extract
(2), and fractions 30,31,32,33,34,41 and
58 (3-8) were analyzed by SDS-PAGE
(15% acrylamide) under reducing con-
ditionsand stained with silver nitrate.
the fraction (-300 pmol) was subjected to NH2-terminal sequence analysis (Table
I) . Comparison of the NH2-terminal sequence to known neutrophil and eosinophil
proteins revealed an identity with the recently published NH2-terminal sequence
ofMBP (14) . SDS-PAGE analysis (Fig . 2) revealed an ti14-kD molecule, similar
to the value previously reported for human MBP (29) .
Antimicrobial Activity oftheMBP-rich Fraction.
￿
The 14-kD, MBP-rich fraction proved
to have broad spectrum antimicrobial activity against Gram-negative and Gram-
positive bacteria and fungi (Table II) . The LD5o (defined in Materials and Methods)
was 1 wg/ml againstE. colt and C . albicans and 0.1 ug/ml againstS faecalis . Since
we had noted that lysozyme was often present in the MBP-rich fraction, we tested
the ability of pure human lysozyme (Calbiochem-Behring Corp., San Diego, CA)
to kill the same microorganisms . The LD5o for lysozyme was 6 wg/ml against
S . faecalis, 0.3 gg/ml against C . albicans, and >1 mg/ml (no killing detected) against
E . coli .
Oligonucleotide Probe Design .
￿
The NH2-terminal amino acid sequence determined
for MBP (Table I) contained a region (residues 32-36) suitable for the design of
mixed oligomer probes . A 14-mer mixture of 16 oligomers was synthesized as the
complement to the sequence encoding residues His-Asn-Phe-Asn-Ile (5'
ATA/GTTA/GAAA/GTTA/GTG-3') . The 14-mer mixed oligomer probewas 5' end-
labeled with y[32P] and hybridized to a Northern blot containingE . coli andhuman
rRNA, and to an array of human mRNAs isolated from HL-60, KGla, and SK
hepatoma cells. Hybridization was carried out at 32°C for 24 h under standardO 0 214nm
(2.0 AUFS)
From reference 14.
- 68 kDa
- 45 kDa
- 24 kDa
- 18 kDa
- 15 kDa
riT'~~ITTT-rTT'T I I 14~
10 15 20 25
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Fmcdon Number
oligomer hybridization conditions (24). The oligomer probe hybridized to an N1-
kb mRNA present in HL-60 cells and very little to the control samples (data not
shown). The tentative identification ofa 1-kb mRNA for MBP in this preliminary
analysis was unexpected, since the estimated size for an mRNA encoding a 14-kD
protein is only 400-500 nucleotides.
Identification ofaFull-Length cDNA Encoding MBP .
￿
Messenger RNA isolatedfrom
DMSO-induced HL60 cells was used to construct a cDNA library in XGT10. Ap-
TABLE I
Sequence Comparison of Reverse-Phase Peak 3 to MBP
FiGtn.E 2.
￿
Reverse-phase HPLC
purification of the 14-kD poly-
peptide. Fraction 41 from TSK-
size exclusion chromatography
was adjusted to 0.1% TFA and
further purified by reverse-
phase HPLC as described in
Materials and Methods. Puri-
fied MBP (2 gg) was subjected
to 15% SDS-PAGE (inset) and
silver stained.
14 kD Thr ( ) Arg Tyr Leu Leu Val Arg Ser Leu
MBP' ( ) ( ) Arg Tyr Leu Leu Val Arg Ser Leu
14 kD Gln Thr Phe Ser Gln Ala ( ) Phe Thr ( )
MBP Gln Thr Phe (Ser) Gln Ala ( ) Phe Thr ( )
14 kD Arg Arg ( ) Tyr Arg Gly Asn Leu Val Ser
14 kD Ile His Asn Phe Asn Ile Asn Tyr Arg Ile2300
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TABLE II
Broad Spectrum Antimicrobial Activity of the I4-kD Polypeptide Fraction"
Pathogen
￿
Specific activity
KU/mg
Escherichia coli
￿
45,000
Streptococcusfaecalis
￿
450,000
Candida albicans
￿
45,000
Exclusively composed of MBP (80%) and lysozyme (20%).
proximately 106 independent recombinant clones having a minimum insert size of
300 by were screened for the MBP sequence by hybridization to the mixed 14-mer
probe. Three cDNA clones that hybridized to the oligomer were plaque purified
andfound tocontain inserts rangingfrom400 to 550bp. Theclones were sequenced
and found to contain an open reading frame that matched the NH2-terminal se-
quence ofMBP, beginning, in the longest clone, at residue 14 of 14-kDprotein and
ending at a TGA stop colon 313 by downstream. The 3' end of these clones had
an additional 110 by ofnoncodingsequence, followed by a stretch ofpoly(A). It thus
appeared that these clones represented an incomplete MBP cDNA, lacking the 5'
noncoding and NH2-terminal coding portion.
To determine the actual size of MBP mRNA, the insert fragment from the 550
by clone was labeled by nick-translation and hybridized to a Northern blot con-
taining inducedanduninducedHL-60mRNA. Aprominenthybridizing 1-kb mRNA
species could be observed, identical in size to the mRNA species that hybridized
to the mixed oligomer probe. To identify a full-length MBP cDNA clone, a XGT10
cDNA library was constructed usinguninduced HL-60 mRNA and screened using
the 550-bp MBP probe. 12 positive clones were plaque purified. Seven were ana-
lyzedby Southern mappingand found tocontain insertsof850-900bp, representing
candidates for full-length MBP cDNAclones. Arestriction map ofa representative
cDNA insert is shown in Fig. 3 A. Four ofthese clones were sequenced after sub-
cloning into M-13 vectors. The sequence ofthe full-length cDNA is shown in Fig.
3 B. An open reading frame encompassing the NH2-terminal amino acid sequence
ofMBP extends from the start ofthe clone through nucleotide position 715. The
first ATG colon, at position 49, is surrounded by sequences that closely resemble
consensus mammalian translational initiation codons (GCCACCATGG) (30, 31).
There is a region resembling the hexanucleotide polyadenylation signal sequence
(AATAAA) (32) at position 805, which is followed 13 by laterby a stretch ofadeno-
sine residues. This suggested that the entire coding sequence was contained in the
850-bp MBP cDNA clone.
The deduced amino acid sequence beginning at the initiation codon at position
49 is followed by a 15-amino acid hydrophobic signal peptide, a 90-amino acid
NH2-terminal domain containing one potential N-linked glycosylation site (at
nucleotide position 304), and the 117 residue COOH-terminal domain which con-
tains the previously described MBP (14). The NH2=terminal amino acid sequence
ofthe 14 kDa MBP is thus contained within a 222 residue pre-pro-form, bounded
by the Met initiation codon at position 49 andthe translational termination codon
at position 715. The pro-form ofMBPispredictedtobe 23 kD andthe mature formMcGROGAN ET AL .
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FIGURE 3 .
￿
Restriction map andDNA sequence of MBP,-9 . (A) Restriction map . The cDNA
is bounded by EcoRI sites at both ends . The restriction sites used for sequencing and the region
sequenced are indicated by the arrows below the map . The open reading frame is denoted by
the expanded region. Thehydrophobic sequence identified by computer search as the secretory
signal is shownby the shaded region . The 14-kD MBP sequence is denoted by the crosshatched
region . (B) Nucleotide sequence anddeduced amino acid sequence of MBPl-9 insert. The entire
sequence wasdetermined by the dideoxy chain termination method after subcloning restriction
fragments into M13 mp18 and mp19 vectors . Numbers refer to the nucleotide position immedi-
ately after the Eco RI cloning linker. The Met initiation codon is underlined, as is the amino
acid sequence of the 14-kD protein determined by Edman degradation .
14 kD. There are 12 cysteine residues contained within the pro-form, 9 of which
are located in the MBP domain .
Analysis ofMBPmRNA .
￿
Theexpression ofMBPmRNA in avariety of cell lines
was analyzed by Northern blot hybridization to the 850-bp cDNA clone . Poly(A)-
containing cytoplasmic RNA was isolated and fractionated by electrophoresis on2302
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denaturing formaldehyde gels . TheRNA was then electroblotted to a membrane
and hybridized to 12P-labeled probe prepared by nick translation of the full-length
MPB clone . Fig. 4 shows thatMBP mRNA appears as an -1,000-nucleotide spe-
cies thatwas detected only in HL-60 cells . Uninduced HL-60 cultures (lane 2) con-
tained higher levels of this mRNA than either of the DMSO-induced HL-60 cul-
tures (lanes 3 and 4) . Lane 2, in addition, contained a hybridizingRNA species
migrating as a broad band at 500 nucleotides. Comparable quantities ofRNA from
SK-Hep cells (lane 1) or KG-la, an acute myelogenous leukemia cell line (lane 5),
did not show detectable levels ofMBP mRNA . The Northern hybridization results
are in good agreement with the predicted size of the MBP mRNA of 1,000 bases,
obtained by the addition of 150 bases of poly(A) to the 850-base cDNA clone .
Southern Analysis oftheMBP Gene.
￿
The structure of theMBP gene was examined
by restriction analysis and Southern blot hybridization . GenomicDNA samples iso-
lated from human fibroblasts or from HL-60 cells were digested to completion with
restrictionendonucleases andfractionated by agarose gelelectrophoresis. TheDNA
was electroblotted from the gel to a membrane filter and hybridized understandard
conditions to the "P-labeled MBPcDNA probe. The resulting autoradiograph (Fig .
5) is consistent with the MBP gene having a relatively simple structure . The Eco
RI pattern (lane 1) consists of two bands of -6.5 and 3.8 kb, which suggests that
the gene contains at least one intron, since the cDNA clone does not have internal
Eco RI sites . As predicted from the single Hind III site in the cDNA, two Hind
III fragments were detected (lane 2, human fibroblast DNA; lane 4, HL-60DNA)
that are -5.5 and 2 .7 kb . Only one band of slightly less than 3 kb in size was found
in the Barn HI digest . These results suggest that the MBP gene is <3 kb long and
contains at least one intron . Although notconclusive, this analysis is consistent with
MBP being a single copy gene . The restriction patterns of both HL-60 and HFF
FIGURE 4 .
￿
MBP Northern blot. Poly(A) cytoplasmicRNA sam-
ples, -10 ug per lane, were fractionated on a 1.5% agarose form-
aldehyde gel and electroblotted to amembrane filter. TheRNA
blot was hybridized to nick-translated 850-bp MBP cDNA frag-
ment under stringent conditions . The filter was washed and ex-
posed to x-ray film . RNAsize markers were visualized underUV
light after staining with ethidium bromide. (Lane 1) SK-Hep RNA,
(lane 2) uninduced HL-60RNA, (lane 3) DSMO-induced HL-60
RNA(72 h), (lane 4) DMSO-induced HL-60RNA (40 h), (lane
5) KGIA RNA.McGROGAN ET AL .
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FIGURE 5 .
￿
MBP Southern blot . Human genomicDNA was
digested to completion with Eco RI, Hind III, or BamHI re-
striction endonucleases and 15 Wg of each sample was run on
an 0.8% agarose gel. TheDNAwas electrophoretically trans-
ferred to amembrane filter and hybridized under stringent con-
ditions to the 32P-labeled 850-bp MBP probe. (Lane 1) Eco
RI digest ofHFFDNA, (lane 2) Hind III digest ofHFFDNA,
(lane 3) Bam HI digest of HL-60 DNA, (lane 4) Hind III di-
gest of HFFDNA.
DNA are identical, demonstrating that rearrangement of the MBP gene has not
likely occurred in the HL-60 cell line .
Discussion
The sequence ofthe NH2-terminal 40 amino acids of the purified 14-kD protein
corresponds exactly to residues Thrto6-Ilet41 predicted from the cloned cDNA, and
matches the recently published N-terminal sequence of human MBP (14) . The
predicted size of the polypeptide spanning Thrt°6Tyr222 is 13,800, similar to the ap-
parentM r of the 14-kD protein and to values reported forMBP(29) . The predicted
amino acid composition ofthe deduced sequence corresponds closely to that reported
for human MBP (12).
The most surprising finding of this study was that humanMBP is likely synthe-
sized as an ti25-kD primary translation product and subsequently cleaved to re-
leasethemature 14-kD form . The deducedaminoacid sequence of theMBPcDNA
from HL-60 cells contains a putative leader sequence indicative of a secreted pro-
tein, with a predicted cleavage site for signal peptidase after amino acid 15 or 16 .
There is a potential N-linked glycosylation site at amino acid position 86, which
may contribute to the solubility ofpro-MBP in aqueous solutions . The predicted
23-kDpro-MBP contains 12 cysteine residues, ofwhich9arein theMBPdomain. The
assymmetric distribution of cysteines would place at least one free cysteine in each
domain (NH2-terminal and COOH terminal) of pro-MBP. The presence of free
sulfhydryls in mature MBP is consistent with itsreported tendency to aggregate (33) .
Based on computer analysis, the putative secreted form of the 23 kD molecule
has a predicted pI of 6.0, whereas the 14-kD MBP domain has a predicted pI of
11 .1 . As might be expected, the NH2-terminal domain is predicted to have an ex-2304
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FIGURE 6.
￿
Hydropathic plot of
the MBP precursor sequence.
The full-length amino acid se-
quence encodedbythegenede-
scribed in Fig. 3 was analyzed
for hydrophilic/hydrophobic do-
mains by the method of Kyte
and Doolittle (50).
tremely acidic pI of 3.7. Likewise, the hydropathy plot (Fig. 6), indicates that the
NH2-terminal domain is hydrophilic, whereas the MBP domain (residues 106-222)
is markedly hydrophobic. It would thus appear that the MBP is initially contained
within abipolar molecule that is likely to have markedly different biological proper-
ties from mature MBP
The bipolar nature of pro-MBP is reminiscent of the characteristics of BPI. All
the microbicidal activity of BPI toward Gram-negative bacteria is expressed by the
cationic NH2-terminal 25-kD portion of the molecule (34). The COOH terminus
predicted from the cDNA forBPI is slightly negatively charged, andcontains many
hydrophobic residues (35). Pro-forms also exist for myeloperoxidase, another con-
stituent of the azurophil granule (36); magainin, a 3-kD bactericidal polypeptide
from the skin and mucous membranes of frogs (37); nisin (38), subtilin (38), and
epidermin (39), antibiotic polypeptides of bacterial origin ; and cecropin B, abacte-
ricidal protein from the moth Cecropia (40). In none of these cases has a function
been definitively ascribed to the pro-form. Possible functions include targeting of
the antimicrobial protein to the proper subcellular compartment or to its proper
position within that compartment, maintenance of the cytotoxin in a latent state
to minimize autotoxicity, participation in the activation ofthe molecule or itstransfer
to the target cell, or performance of an additional function that may be unrelated
to microbicidal activity.
MBPwas isolated in these studies from amembrane fraction ofazurophil granules
purified from PMN preparations that contained 3-7% eosinophils. Since the major
source of MBP has been shown to be eosinophils and basophils, it is most likely
that the low level of MBP found in our neutrophil preparations was due to the
copurification of eosinophil granuleproteins with the azurophil granules. However,
our resultsdo not exclude thepossibility that MBP is aminor constituent ofneutro-
phils, despite the reported lack of reactivity of anti-MBP antisera with neutrophils
by immunofluorescence (41) and immunoelectronmicroscopy (42). Thus, it remains
unclear whether primary eosinophils and basophils are the only PMN that contain
MBP (43), or whether MBP is a consituent of all three types of PMN. We are cur-
rently trying to resolve this issue by separating eosinophils and neutrophils on a
preparative scale without rupturing either cell population .McGROGAN ET AL.
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Finally, it wassurprising that MBPwasassociated with broad spectrum antimicrobial
activity toward bacteria and fungi, properties MBP was previously reported to lack.
Upon closer study, we discovered that our preparations often were contaminated
with lysozyme. However, authenticlysozyme lacked the abilityto kill Gram-negative
bacteria, and was far less potent at killing Gram-positive bacteria than the 14 kD
fraction. It remains for further study to define the contribution of MBP to these
results and to determine whether MBP and lysozyme act synergistically. Prelimi-
nary findings with pure MBP, free of lysozyme, confirm the results reported here
with the 14 kD fraction, and will be presented elsewhere as part of a more definitive
analysis of MBP bioactivity.
In previous studies, MBP was toxic to schistosomula of S mansoni (44),
trypomastigotes of T . cruzi (45), and a varietyof mammalian cells (46) at -100-fold
higher concentrations than required in the present studies with bacteria and fungi.
Proteins that crossreact immunologically with MBP have been observed at concen-
trations above 10 gg/ml in sputa, pleural fluid, and sera of patients with asthma,
eosinophilic pneumonia, and hypereosinophilia (47, 48). The serum level of MBP-
related molecules normally reaches 7.5 pg/ml shortlybefore parturition (49). It will
be of interest to express both recombinant MBP andrecombinant pro-MBP, in order
to compare their antimicrobial properties, toxicities, and mechanisms of action, and
to define their relatedness to the cytotoxic polypeptides of mononuclear leukocytes.
Summary
A 14-kD protein was purified from human PMNs and its N112-terminal sequence
was determined. Comparison of a portion of the NH2-terminal sequence of this pro-
tein to the recently reported NH2-terminal sequence of eosinophil major basic pro-
tein (MBP) showed them to be identical. To aidfurther characterization ofthe struc-
tural and functional properties of this molecule, we isolated from an HL-60 cDNA
library a single class of cDNA clones whose sequence matched exactly the NH2-
terminal amino acid sequence ofthe 14-kD polypeptide. Northern analysis ofHL-60
cells suggests that MBP is constitutively expressedin HL-60 cells andis highly tran-
scribed from asingle copy gene. The sequence of thefull-length cDNA clones predicts
that MBPis synthesizedas a23-kD precursorform (pro-MBP) whichis subsequently
cleaved to release the mature 14-kD MBP The putative pro-MBP has a predicted
pI of 6.0, but both the charged and the hydrophobic residues are assymetrically dis-
tributed, creating a bipolar molecule. The NH2-terminal half has a predicted pI
of 3.7 and is hydrophilic, while the COOH-terminal half (corresponding to mature
MBP) has a predicted pI of 11 .1 and is hydrophobic.
Receivedfor publication 23 August 1988.
Note added in proof Afterthis paperwas submitted, the complete aminoacid sequence ofmature
MBP and the cloning of the MBP precursor were reported (51, 52).
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